866-997-4948(US-Canada Toll Free)

Myelodysplastic Syndrome - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Nov 2016

Category :

Pharmaceutical

No. of Pages : 749 Pages

Myelodysplastic Syndrome - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myelodysplastic Syndrome Pipeline Review, H2 2016, provides an overview of the Myelodysplastic Syndrome (Oncology) pipeline landscape.

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages of the disease. Symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding and frequent infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myelodysplastic Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myelodysplastic Syndrome (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 11, 62, 55, 3, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 6, 7, 2, 1 and 2 molecules, respectively.Myelodysplastic Syndrome.

Myelodysplastic Syndrome (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
- The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 7
Myelodysplastic Syndrome Overview 8
Therapeutics Development 9
Myelodysplastic Syndrome - Therapeutics under Development by Companies 11
Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 18
Myelodysplastic Syndrome - Pipeline Products Glance 20
Myelodysplastic Syndrome - Products under Development by Companies 24
Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 34
Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 35
Myelodysplastic Syndrome - Therapeutics Assessment 131
Drug Profiles 153
Myelodysplastic Syndrome - Dormant Projects 709
Myelodysplastic Syndrome - Discontinued Products 716
Myelodysplastic Syndrome - Product Development Milestones 718
Appendix 730

List of Tables
Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016 28
Number of Products under Development by Companies, H2 2016 29
Number of Products under Development by Companies, H2 2016 (Contd..1) 30
Number of Products under Development by Companies, H2 2016 (Contd..2) 31
Number of Products under Development by Companies, H2 2016 (Contd..3) 32
Number of Products under Development by Companies, H2 2016 (Contd..4) 33
Number of Products under Development by Companies, H2 2016 (Contd..5) 34
Number of Products under Development by Companies, H2 2016 (Contd..6) 35
Number of Products under Investigation by Universities/Institutes, H2 2016 37
Comparative Analysis by Late Stage Development, H2 2016 38
Comparative Analysis by Clinical Stage Development, H2 2016 39
Comparative Analysis by Early Stage Development, H2 2016 40
Comparative Analysis by Unknown Stage Development, H2 2016 41
Products under Development by Companies, H2 2016 42
Products under Development by Companies, H2 2016 (Contd..1) 43
Products under Development by Companies, H2 2016 (Contd..2) 44
Products under Development by Companies, H2 2016 (Contd..3) 45
Products under Development by Companies, H2 2016 (Contd..4) 46
Products under Development by Companies, H2 2016 (Contd..5) 47
Products under Development by Companies, H2 2016 (Contd..6) 48
Products under Development by Companies, H2 2016 (Contd..7) 49
Products under Development by Companies, H2 2016 (Contd..8) 50
Products under Development by Companies, H2 2016 (Contd..9) 51
Products under Investigation by Universities/Institutes, H2 2016 52
Myelodysplastic Syndrome - Pipeline by 4SC AG, H2 2016 53
Myelodysplastic Syndrome - Pipeline by AbbVie Inc, H2 2016 54
Myelodysplastic Syndrome - Pipeline by Acceleron Pharma Inc, H2 2016 55
Myelodysplastic Syndrome - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 56
Myelodysplastic Syndrome - Pipeline by Aeglea BioTherapeutics Inc, H2 2016 57
Myelodysplastic Syndrome - Pipeline by Agios Pharmaceuticals Inc, H2 2016 58
Myelodysplastic Syndrome - Pipeline by Aileron Therapeutics Inc, H2 2016 59
Myelodysplastic Syndrome - Pipeline by Altor BioScience Corp, H2 2016 60
Myelodysplastic Syndrome - Pipeline by Amgen Inc, H2 2016 61
Myelodysplastic Syndrome - Pipeline by Apogenix GmbH, H2 2016 62
Myelodysplastic Syndrome - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 63
Myelodysplastic Syndrome - Pipeline by Arno Therapeutics Inc, H2 2016 64
Myelodysplastic Syndrome - Pipeline by Arog Pharmaceuticals Inc, H2 2016 65
Myelodysplastic Syndrome - Pipeline by Array BioPharma Inc, H2 2016 66
Myelodysplastic Syndrome - Pipeline by Astex Pharmaceuticals Inc, H2 2016 67
Myelodysplastic Syndrome - Pipeline by Atara Biotherapeutics Inc, H2 2016 68
Myelodysplastic Syndrome - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 69
Myelodysplastic Syndrome - Pipeline by BerGenBio AS, H2 2016 70
Myelodysplastic Syndrome - Pipeline by Bio-Path Holdings Inc, H2 2016 71
Myelodysplastic Syndrome - Pipeline by BioLineRx Ltd, H2 2016 72
Myelodysplastic Syndrome - Pipeline by BioLite Inc, H2 2016 73
Myelodysplastic Syndrome - Pipeline by Boehringer Ingelheim GmbH, H2 2016 74
Myelodysplastic Syndrome - Pipeline by Boston Biomedical Inc, H2 2016 75
Myelodysplastic Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2016 76
Myelodysplastic Syndrome - Pipeline by Cantex Pharmaceuticals Inc, H2 2016 77
Myelodysplastic Syndrome - Pipeline by Celgene Corp, H2 2016 78
Myelodysplastic Syndrome - Pipeline by Celldex Therapeutics Inc, H2 2016 79
Myelodysplastic Syndrome - Pipeline by Cellerant Therapeutics Inc, H2 2016 80
Myelodysplastic Syndrome - Pipeline by Celyad SA, H2 2016 81
Myelodysplastic Syndrome - Pipeline by Constellation Pharmaceuticals Inc, H2 2016 82
Myelodysplastic Syndrome - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 83
Myelodysplastic Syndrome - Pipeline by CrystalGenomics Inc, H2 2016 84
Myelodysplastic Syndrome - Pipeline by CTI BioPharma Corp, H2 2016 85
Myelodysplastic Syndrome - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 86
Myelodysplastic Syndrome - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 87
Myelodysplastic Syndrome - Pipeline by DiNonA Inc., H2 2016 88
Myelodysplastic Syndrome - Pipeline by Eisai Co Ltd, H2 2016 89
Myelodysplastic Syndrome - Pipeline by Eleos Inc, H2 2016 90
Myelodysplastic Syndrome - Pipeline by Eli Lilly and Company, H2 2016 91
Myelodysplastic Syndrome - Pipeline by EpiZyme Inc, H2 2016 92
Myelodysplastic Syndrome - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 93
Myelodysplastic Syndrome - Pipeline by FORMA Therapeutics Inc, H2 2016 94
Myelodysplastic Syndrome - Pipeline by Fujifilm Corp, H2 2016 95
Myelodysplastic Syndrome - Pipeline by Gamida Cell Ltd, H2 2016 96
Myelodysplastic Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 97
Myelodysplastic Syndrome - Pipeline by H3 Biomedicine Inc, H2 2016 98
Myelodysplastic Syndrome - Pipeline by IGF Oncology LLC, H2 2016 99
Myelodysplastic Syndrome - Pipeline by ImmunoGen Inc, H2 2016 100
Myelodysplastic Syndrome - Pipeline by Incyte Corp, H2 2016 101
Myelodysplastic Syndrome - Pipeline by Io Therapeutics Inc, H2 2016 102
Myelodysplastic Syndrome - Pipeline by Jazz Pharmaceuticals Plc, H2 2016 103
Myelodysplastic Syndrome - Pipeline by Jiangsu Hansoh Pharmaceutical Co Ltd, H2 2016 104
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson, H2 2016 105
Myelodysplastic Syndrome - Pipeline by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., H2 2016 106
Myelodysplastic Syndrome - Pipeline by Juno Therapeutics Inc, H2 2016 107
Myelodysplastic Syndrome - Pipeline by JW Pharmaceutical Corp, H2 2016 108
Myelodysplastic Syndrome - Pipeline by Kainos Medicine Inc, H2 2016 109
Myelodysplastic Syndrome - Pipeline by KaloBios Pharmaceuticals Inc, H2 2016 110
Myelodysplastic Syndrome - Pipeline by Karyopharm Therapeutics Inc, H2 2016 111
Myelodysplastic Syndrome - Pipeline by Kiadis Pharma NV, H2 2016 112
Myelodysplastic Syndrome - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 113
Myelodysplastic Syndrome - Pipeline by La Jolla Pharmaceutical Company, H2 2016 114
Myelodysplastic Syndrome - Pipeline by Lixte Biotechnology Holdings Inc, H2 2016 115
Myelodysplastic Syndrome - Pipeline by MacroGenics Inc, H2 2016 116
Myelodysplastic Syndrome - Pipeline by Mateon Therapeutics Inc, H2 2016 117
Myelodysplastic Syndrome - Pipeline by medac GmbH, H2 2016 118
Myelodysplastic Syndrome - Pipeline by MedImmune LLC, H2 2016 119
Myelodysplastic Syndrome - Pipeline by MEI Pharma Inc, H2 2016 120
Myelodysplastic Syndrome - Pipeline by Merck & Co Inc, H2 2016 121
Myelodysplastic Syndrome - Pipeline by Merus NV, H2 2016 122
Myelodysplastic Syndrome - Pipeline by Mesoblast Ltd, H2 2016 123
Myelodysplastic Syndrome - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 124
Myelodysplastic Syndrome - Pipeline by Mirati Therapeutics Inc, H2 2016 125
Myelodysplastic Syndrome - Pipeline by Nemucore Medical Innovations Inc, H2 2016 126
Myelodysplastic Syndrome - Pipeline by Novartis AG, H2 2016 127
Myelodysplastic Syndrome - Pipeline by Onconova Therapeutics Inc, H2 2016 128
Myelodysplastic Syndrome - Pipeline by OncoTherapy Science Inc, H2 2016 129
Myelodysplastic Syndrome - Pipeline by Opsona Therapeutics Ltd, H2 2016 130
Myelodysplastic Syndrome - Pipeline by Pfizer Inc, H2 2016 131
Myelodysplastic Syndrome - Pipeline by Pharma Mar SA, H2 2016 132
Myelodysplastic Syndrome - Pipeline by Regen BioPharma Inc, H2 2016 133
Myelodysplastic Syndrome - Pipeline by Rich Pharmaceuticals Inc, H2 2016 134
Myelodysplastic Syndrome - Pipeline by Seattle Genetics Inc, H2 2016 135
Myelodysplastic Syndrome - Pipeline by Stemline Therapeutics Inc, H2 2016 136
Myelodysplastic Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 137
Myelodysplastic Syndrome - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 138
Myelodysplastic Syndrome - Pipeline by Syndax Pharmaceuticals Inc, H2 2016 139
Myelodysplastic Syndrome - Pipeline by Takara Bio Inc, H2 2016 140
Myelodysplastic Syndrome - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 141
Myelodysplastic Syndrome - Pipeline by Targazyme Inc, H2 2016 142
Myelodysplastic Syndrome - Pipeline by TetraLogic Pharmaceuticals, H2 2016 143
Myelodysplastic Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016 144
Myelodysplastic Syndrome - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H2 2016 145
Myelodysplastic Syndrome - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 146
Myelodysplastic Syndrome - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 147
Myelodysplastic Syndrome - Pipeline by Trillium Therapeutics Inc, H2 2016 148
Assessment by Monotherapy Products, H2 2016 149
Assessment by Combination Products, H2 2016 150
Number of Products by Stage and Target, H2 2016 152
Number of Products by Stage and Mechanism of Action, H2 2016 160
Number of Products by Stage and Route of Administration, H2 2016 168
Number of Products by Stage and Molecule Type, H2 2016 170
Myelodysplastic Syndrome - Dormant Projects, H2 2016 727
Myelodysplastic Syndrome - Dormant Projects (Contd..1), H2 2016 728
Myelodysplastic Syndrome - Dormant Projects (Contd..2), H2 2016 729
Myelodysplastic Syndrome - Dormant Projects (Contd..3), H2 2016 730
Myelodysplastic Syndrome - Dormant Projects (Contd..4), H2 2016 731
Myelodysplastic Syndrome - Dormant Projects (Contd..5), H2 2016 732
Myelodysplastic Syndrome - Dormant Projects (Contd..6), H2 2016 733
Myelodysplastic Syndrome - Discontinued Products, H2 2016 734
Myelodysplastic Syndrome - Discontinued Products (Contd..1), H2 2016 735

List of Figures
Number of Products under Development for Myelodysplastic Syndrome, H2 2016 27
Number of Products under Development for Myelodysplastic Syndrome - Comparative Analysis, H2 2016 28
Number of Products under Development by Companies, H2 2016 29
Number of Products under Investigation by Universities/Institutes, H2 2016 36
Comparative Analysis by Clinical Stage Development, H2 2016 39
Comparative Analysis by Early Stage Products, H2 2016 40
Assessment by Monotherapy Products, H2 2016 149
Number of Products by Top 10 Targets, H2 2016 151
Number of Products by Stage and Top 10 Targets, H2 2016 151
Number of Products by Top 10 Mechanism of Actions, H2 2016 159
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 159
Number of Products by Routes of Administration, H2 2016 167
Number of Products by Stage and Routes of Administration, H2 2016 167
Number of Products by Top 10 Molecule Types, H2 2016 169
Number of Products by Stage and Top 10 Molecule Types, H2 2016 169

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *